C urrent treatment guidelines for chronic hepatitis B (CHB) base treatment recommendations on a combination of serum alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and hepatic necroinflammation/fibrosis. [1] [2] [3] Although accurate assessment of liver histologic abnormalities is crucial for determining disease severity, liver biopsy rarely is performed and the findings may not always be accurate. Although elastography and serologic markers can be used to assess fibrosis, in clinical practice treatment decisions often are based on ALT and HBV DNA alone. Thus, it is typical for no further assessment when there is persistently normal ALT (PNALT) levels. This is problematic in some patients given multiple studies of Asian CHB patients showing significant fibrosis in a substantial percentage of patients with PNALT, including both hepatitis B e antigen-positive patients (range, 22.5%-49.4%) and hepatitis B e antigen-negative patients (range, 13.8%-35.9%). It is clear that many patients with PNALT may be in need of treatment. [4] [5] [6] [7] Our study aimed to evaluate the prevalence of fibrosis among treatmentnaive CHB patients with increased HBV DNA and PNALT levels using serologic testing, radiography, and shear wave elastography (SWE) to assess the correlation between these noninvasive measures of fibrosis.
Methods
Consecutive treatment-naive noncirrhotic Asian CHB adults (age, men 40 y; women 50 y) with increased HBV DNA and PNALT levels (<20 U/L for women and <30 U/L for men) at a community gastroenterology clinic from June 2015 to September 2016 were evaluated prospectively to determine the prevalence of hepatic fibrosis (assessed using serology [FIB-4, aspartate aminotransferase to platelet ratio index (APRI), and FibroTest/Fibrosure; LabCorp, Burlington, NC], radiography, and SWE 
Statistical Analysis
Comparisons of F2 and higher stage fibrosis used chi-square testing. Multivariate logistic regression models evaluated for predictors of stage F2 and higher fibrosis. Age and sex were selected for inclusion in the model a priori; additional variables were selected if they were statistically significant in univariate models (P < .10). The final model included age, sex, body mass index (BMI), and concurrent diabetes. Correlations between noninvasive tests were analyzed with the Pearson correlation coefficient. Analyses were performed using Stata statistical package (version 13, College Station, TX), with a 2-tailed P value of less than .05 indicating statistical significance. The study was approved by the Silicon Valley Research Institute Institutional Review Board.
Results
Among 136 Asian CHB patients with PNALT and increased HBV DNA levels (49.3% male; mean age, 55.1 y; SD, 10.8 y), 5.1% had FIB-4 scores greater than 3.25, 4.4% had APRI scores greater than 0.7, and 5.8% had a FibroTest score of 0.59 or higher. On elastography, 28.1% of CHB patients with PNALT and increased HBV DNA levels had stage F2 or higher fibrosis and 4.4% had stage F3 or higher fibrosis.
Men (vs women) and CHB patients with a BMI of 25 or higher (vs BMI < 25) had significantly higher rates of stage F2 or higher fibrosis on elastography. On multivariate regression, men (vs women: odds ratio, 2.97; 95% confidence interval, 1.29-6.57; P ¼ .011) and BMI of 25 or higher (vs BMI<25: odds ratio, 2.73; 95% confidence interval, 1.18-6.28; P ¼ .0189) were significant predictors of stage F2 or higher fibrosis (Figure 1) . By using the Pearson correlation coefficient, elastography assessment of hepatic fibrosis showed suboptimal correlation with FibroTest, FIB-4, and APRI.
Discussion
Among our community-based population of CHB patients with PNALT and increased HBV DNA levels, 28.1% had stage F2 or higher fibrosis and 4.4% had stage F3 or higher fibrosis by SWE. Without assessment of fibrosis, these CHB patients would not be eligible for treatment based on current international liver society guidelines, and all patients in the current study we have identified as having significant fibrosis would have fallen through the cracks. [1] [2] [3] Unfortunately, in clinical practice, the failure to assess fibrosis is too common. There often is patient reluctance to undergo a biopsy because of the expense and concerns about pain and complications. Even when it is performed, biopsy results are not always accurate because of interobserver and intra-observer variability and sampling error. 8 Although there has been increasing interest in noninvasive methods to assess fibrosis, depending on the clinical setting even elastography is not always performed with all CHB patients, especially those with PNALT.
The findings of our study and previous studies showing significant fibrosis in a substantial percentage of Asian CHB patients with PNALT make a strong case that many patients with PNALT may be in need of treatment and assessment of fibrosis strongly should be considered. [4] [5] [6] [7] Given the poor correlation we observed between elastography and serologic markers of fibrosis, the use of serologic markers alone may not assess fibrosis severity accurately, but rather should be combined with other modalities, including radiographic testing, to improve accuracy when elastography is not available. Although elastography alone may provide reasonable accuracy in fibrosis assessment, elastography is not readily available in all practice settings.
